Narayanan, PadmaKumar <br/><br/>
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia.  [electronic resource] 

 -  Nucleic acid therapeutics  04 2020 
 - 94-103 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2159-3345 
<br/><br/><label>Standard No.: </label>10.1089/nat.2019.0829  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Amyloid Neuropathies, Familial--drug therapy<br/>Female<br/>Genetic Predisposition to Disease<br/>Humans<br/>Immune System Diseases--chemically induced<br/>Immunoglobulin G<br/>Intracranial Hemorrhages--chemically induced<br/>Male<br/>Middle Aged<br/>Oligodeoxyribonucleotides, Antisense--administration & dosage<br/>Oligonucleotides--administration & dosage<br/>Oligonucleotides, Antisense--administration & dosage<br/>Quality of Life<br/>Thrombocytopenia--blood